Search results for "GK"
showing 10 items of 254 documents
LDH uzticamība ne-Hodžkina limfomas ārstēšanas terapijas efektivitātēs izvērtēšanai
2022
Saikne starp laktātdehidrogenāzi un ne-Hodžkina limfomu ir pierādīta, taču laktātdehidrogenāzes loma ir palikusi tikai prognostiska. Šajā pētījumā mēs nolēmām izpētīt, vai laktāta dehidrogenāze varētu aizstāt radioloģiskus izmeklējumus, piemēram, datortomogrāfiju un pozitronu emisijas tomogrāfiju,lai izvērtētu ne-Hodžkina limfomas ārstēšanas efektivitāti. Tika veikts retrospektīvs kvantitatīvs pētījums. Tika atlasīti 39 pacienti no Paula Stradiņa Klīniskās universitātes slimnīcas. Tika analizēti pacienta laboratoriskie un radioloģiskie izmeklējumi, mēs analizējām datus, izmantojot SPSS. Pacientiem diagnozes noteikšanas brīdī bija visaugstākais LDH līmenis, un ārstēšanas laikā LDH līmenis sa…
Teori i praksis - praksis i teori. GLU-studenters refleksjoner om fag og didaktikk
2017
De siste tiars forskning, samfunnsdebatt og politikkutforming knyttet til skolesektoren har vaert preget av diskusjoner om hva det egentlig innebaerer a vaere en kompetent laerer, og hvordan de to laeringsarenaene i laererutdanningene – teoriarenaen og praksisarenaen – best kan utfylle hverandre for a utdanne kompetente laerere. I denne artikkelen presenterer vi resultatene fra en undersokelse blant grunnskolelaererstudenter pa en utdanningsinstitusjons grunnskolelaererutdanning for 1.–7. trinn. I undersokelsen har vi rettet blikket mot studentenes opplevelser av laererrollen og av sammenhengen mellom teoriarenaen og praksisarenaen. Dette har vi gjort i tilknytning til ett spesifikt undervi…
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
2020
With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …
Empirical measures and Vlasov hierarchies
2013
The present note reviews some aspects of the mean field limit for Vlasov type equations with Lipschitz continuous interaction kernel. We discuss in particular the connection between the approach involving the N-particle empirical measure and the formulation based on the BBGKY hierarchy. This leads to a more direct proof of the quantitative estimates on the propagation of chaos obtained on a more general class of interacting systems in [S.Mischler, C. Mouhot, B. Wennberg, arXiv:1101.4727]. Our main result is a stability estimate on the BBGKY hierarchy uniform in the number of particles, which implies a stability estimate in the sense of the Monge-Kantorovich distance with exponent 1 on the i…
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
2021
Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
2018
Abstract A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of “heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL…
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final …
2016
Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate. Results B…
Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate
2018
Abstract Background Acquired angioedema due to C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is a serious condition that may result in life-threatening asphyxiation due to laryngeal edema. It is associated with malignant B-cell lymphoma and other disorders. The purpose of this study was to describe the characteristics and associated disorders of patients with AAE-C1-INH and assess the efficacy of plasma-derived C1-INH concentrate (pdC1-INH) in the treatment of AAE-C1-INH. Forty-four patients with AAE-C1-INH from the Angioedema Outpatient Service of Mainz were assessed for associated disorders. In 32 of these patients, the duration of swelling attacks was measured before and after treatment …
Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP
2016
Objectives: The purpose of our retrospective review of prospectively acquired Whole Body Magnetic Resonance (WB-MRI) scans was to assess the incidence of osteonecrosis in patients who received different chemotherapies. Methods: We evaluated the WB-MRI scans performed on 42 patients with Hodgkin Lymphoma treated by three chemotherapy regimens (6ABVD, 2ABVD + 4BEACOPP, 2ABVD + 8BEACOPP), excluding patients with the main risk factors for osteonecrosis. Results: Six out of seven patients (86 %) who received eight BEACOPP and one out of five patients (20 %) treated by four BEACOPP presented osteonecrosis, with a statistically significant difference of frequency between the two groups of patients…
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted …
2013
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients…